Corrigendum to “Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis” [Pharmacol. Res. 188 (2023) 106668]
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-10-01
|
| Series: | Pharmacological Research |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1043661823002785 |
| _version_ | 1797660501581234176 |
|---|---|
| author | Tianyao Lei Tianwei Xu Niu Zhang Xiaoteng Zou Ziyue Kong Chenchen Wei Zhaoxia Wang |
| author_facet | Tianyao Lei Tianwei Xu Niu Zhang Xiaoteng Zou Ziyue Kong Chenchen Wei Zhaoxia Wang |
| author_sort | Tianyao Lei |
| collection | DOAJ |
| first_indexed | 2024-03-11T18:31:47Z |
| format | Article |
| id | doaj.art-474768669fa941eb8d406c0f9dd5ec21 |
| institution | Directory Open Access Journal |
| issn | 1096-1186 |
| language | English |
| last_indexed | 2024-03-11T18:31:47Z |
| publishDate | 2023-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Pharmacological Research |
| spelling | doaj.art-474768669fa941eb8d406c0f9dd5ec212023-10-13T11:03:40ZengElsevierPharmacological Research1096-11862023-10-01196106922Corrigendum to “Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis” [Pharmacol. Res. 188 (2023) 106668]Tianyao Lei0Tianwei Xu1Niu Zhang2Xiaoteng Zou3Ziyue Kong4Chenchen Wei5Zhaoxia Wang6Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, PR ChinaDepartment of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, PR ChinaDepartment of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, PR ChinaDepartment of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, PR ChinaDepartment of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, PR ChinaDepartment of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, PR ChinaCorrespondence to: Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, PR China.; Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, PR Chinahttp://www.sciencedirect.com/science/article/pii/S1043661823002785 |
| spellingShingle | Tianyao Lei Tianwei Xu Niu Zhang Xiaoteng Zou Ziyue Kong Chenchen Wei Zhaoxia Wang Corrigendum to “Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis” [Pharmacol. Res. 188 (2023) 106668] Pharmacological Research |
| title | Corrigendum to “Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis” [Pharmacol. Res. 188 (2023) 106668] |
| title_full | Corrigendum to “Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis” [Pharmacol. Res. 188 (2023) 106668] |
| title_fullStr | Corrigendum to “Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis” [Pharmacol. Res. 188 (2023) 106668] |
| title_full_unstemmed | Corrigendum to “Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis” [Pharmacol. Res. 188 (2023) 106668] |
| title_short | Corrigendum to “Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis” [Pharmacol. Res. 188 (2023) 106668] |
| title_sort | corrigendum to anlotinib combined with osimertinib reverses acquired osimertinib resistance in nsclc by targeting the c met myc axl axis pharmacol res 188 2023 106668 |
| url | http://www.sciencedirect.com/science/article/pii/S1043661823002785 |
| work_keys_str_mv | AT tianyaolei corrigendumtoanlotinibcombinedwithosimertinibreversesacquiredosimertinibresistanceinnsclcbytargetingthecmetmycaxlaxispharmacolres1882023106668 AT tianweixu corrigendumtoanlotinibcombinedwithosimertinibreversesacquiredosimertinibresistanceinnsclcbytargetingthecmetmycaxlaxispharmacolres1882023106668 AT niuzhang corrigendumtoanlotinibcombinedwithosimertinibreversesacquiredosimertinibresistanceinnsclcbytargetingthecmetmycaxlaxispharmacolres1882023106668 AT xiaotengzou corrigendumtoanlotinibcombinedwithosimertinibreversesacquiredosimertinibresistanceinnsclcbytargetingthecmetmycaxlaxispharmacolres1882023106668 AT ziyuekong corrigendumtoanlotinibcombinedwithosimertinibreversesacquiredosimertinibresistanceinnsclcbytargetingthecmetmycaxlaxispharmacolres1882023106668 AT chenchenwei corrigendumtoanlotinibcombinedwithosimertinibreversesacquiredosimertinibresistanceinnsclcbytargetingthecmetmycaxlaxispharmacolres1882023106668 AT zhaoxiawang corrigendumtoanlotinibcombinedwithosimertinibreversesacquiredosimertinibresistanceinnsclcbytargetingthecmetmycaxlaxispharmacolres1882023106668 |